Multiclass <scp>HCV</scp> resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapiesVelia Chiara Di Maio, Francesca Ceccherini‐Silberstein, Valeria Cento et al.|Liver International|2017Cited by 90
Forecasting Hepatitis C liver disease burden on real‐life data. Does the <i>hidden iceberg</i> matter to reach the elimination goals?Loreta A. Kondili, Massimo Zuin, Luchino Chessa et al.|Liver International|2018Cited by 45
Prevalence of anti-HCV among spouses and offspring of anti-HCV positive subjects: an Italian multicentre study.N. Caporaso, Gianni Pastore, Antonio Ascione et al.|PubMed|1995Cited by 19
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosisAntonio Ascione, N. Caporaso, M. De Luca et al.|Infection|2018Cited by 8
Gender Differences in HCV Chronic Liver Disease: A Real Life Evaluation in Piter (Piattaforma Italiana per Lo Studio Della Terapia Delle Epatiti Virali) Cohort StudyLoreta A. Kondili, Claudio Maria Mastroianni, Maria Giovanna Quaranta et al.|Journal of Hepatology|2016Cited by 4